menu

Tryptase Testing: Clinical Utility and Application During COVID-19 Vaccination Reactions

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Tryptase Testing: Clinical Utility and Application During COVID-19 Vaccination Reactions

0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    What is the risk of anaphylaxis following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19)? Are you familiar with the role of serum tryptase testing in patients with a suspected anaphylactic reaction?  Expert faculty, Dr. Cem Akin, discusses serum tryptase testing and its importance in assessing anaphylaxis in response to COVID-19 vaccination. This moderated discussion is enhanced with animation, key takeaways, and support slides to provide an engaging learning experience.

    Serum tryptase plays an important diagnostic role in the setting of mast cell activation resulting from a variety of causes, including mastocytosis and SARS-CoV-2 vaccination. Emergency medicine specialists, allergists, and primary care providers serve as the first-line responders to patients experiencing the effects of mast cell activation. The measurement of tryptase levels helps confirm diagnoses and inform management decisions for these life-threatening disorders. This education enables multidisciplinary clinicians to identify patients at risk of mast cell activation due to a variety of causes and employ appropriate use of tryptase testing across acute and follow-up care settings.

  • Disclosure of Conflicts of Interest

    The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

    The following financial relationships have been provided:
    Cem Akin, MD, PhD (Faculty)
    Consultant: Blueprint, Novartis

    Jennifer Caudle, DO (Moderator)
    No relationships to disclose

    Discussion of Off-Label, Investigational, or Experimental Drug/Device Use of the approved tryptase assay for applications other than diagnosis of mastocytosis.

    ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

  • Target Audience

    This activity is intended for allergists, emergency medicine clinicians, primary care clinicians, and other healthcare providers.

  • Learning Objectives

    Upon completion of this activity, participants will be able to:

    • Employ timely, guideline-based diagnostic testing for the evaluation of patients with suspected mastocytosis
    • Describe the role of tryptase and its measurement to confirm diagnoses of mastocytosis and anaphylaxis
    • Recognize the role of tryptase testing in the setting of SARS-CoV-2 (COVID-19) vaccine-associated anaphylaxis
  • Accreditation and Credit Designation Statements

    The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

    This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

    This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    Supported by an educational grant from Phadia US Inc. a part of Thermo Fisher Scientific.

  • Method of Participation

    This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    What is the risk of anaphylaxis following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19)? Are you familiar with the role of serum tryptase testing in patients with a suspected anaphylactic reaction?  Expert faculty, Dr. Cem Akin, discusses serum tryptase testing and its importance in assessing anaphylaxis in response to COVID-19 vaccination. This moderated discussion is enhanced with animation, key takeaways, and support slides to provide an engaging learning experience.

    Serum tryptase plays an important diagnostic role in the setting of mast cell activation resulting from a variety of causes, including mastocytosis and SARS-CoV-2 vaccination. Emergency medicine specialists, allergists, and primary care providers serve as the first-line responders to patients experiencing the effects of mast cell activation. The measurement of tryptase levels helps confirm diagnoses and inform management decisions for these life-threatening disorders. This education enables multidisciplinary clinicians to identify patients at risk of mast cell activation due to a variety of causes and employ appropriate use of tryptase testing across acute and follow-up care settings.

  • Disclosure of Conflicts of Interest

    The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

    The following financial relationships have been provided:
    Cem Akin, MD, PhD (Faculty)
    Consultant: Blueprint, Novartis

    Jennifer Caudle, DO (Moderator)
    No relationships to disclose

    Discussion of Off-Label, Investigational, or Experimental Drug/Device Use of the approved tryptase assay for applications other than diagnosis of mastocytosis.

    ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

  • Target Audience

    This activity is intended for allergists, emergency medicine clinicians, primary care clinicians, and other healthcare providers.

  • Learning Objectives

    Upon completion of this activity, participants will be able to:

    • Employ timely, guideline-based diagnostic testing for the evaluation of patients with suspected mastocytosis
    • Describe the role of tryptase and its measurement to confirm diagnoses of mastocytosis and anaphylaxis
    • Recognize the role of tryptase testing in the setting of SARS-CoV-2 (COVID-19) vaccine-associated anaphylaxis
  • Accreditation and Credit Designation Statements

    The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

    This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

    This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    Supported by an educational grant from Phadia US Inc. a part of Thermo Fisher Scientific.

  • Method of Participation

    This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule4 Dec 2021
Webpack App